AecorBio Inc., formerly known as HBC Immunology Inc, has successfully completed a further equity financing round of $1.5m from existing and new investors at a company valuation of $30 million. This funding will enable AecorBio to complete the investigational work of its lead peptide candidate FT-002a, in advanced prostate cancer, to enable an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) in 2026. Filing the IND will represent a critical milestone, paving the way ...

Core Insights - HBC has appointed Paul Bruhn as Head of New Business Development, bringing over 25 years of experience in healthcare and medical nutrition [1][2] - The company has developed a unique portfolio of bioactive ingredients derived from salmon, including OmeGo®, ProGo®, NT-II™, and PetGo®, which are scientifically backed and sustainable [3][4] - HBC emphasizes scientific evidence in its product development, leading to academic partnerships and the identification of unique health benefits [5][6] Company Overview - HBC is a Norwegian consumer and pet health company focused on sustainability and optimal utilization of natural resources, upcycling side streams of the salmon industry [3][6] - The company is listed on the Oslo Stock Exchange under the ticker "HBC" [7] Product Portfolio - Key products include ProGo®, a mix of bioactive peptides and collagen; OmeGo®, a whole salmon oil; and CalGo® / NT-II®, a salmon bone powder for bone and joint health [4][5] - OmeGo® is noted for its full spectrum of Omega fatty acids, being 100% natural and clinically proven for various health benefits [3][5] Market Focus - HBC aims to address market needs for clinically backed nutrition sources, particularly in Asia, China, and the ANZ region [2][3] - The company is exploring potential therapeutics through its biotech-focused spin-off, HBC Immunology, targeting prostate and ovarian cancer, as well as asthma treatments [6]

Financial Performance - HBC recorded total operating revenues of NOK 68.4 million in Q2 2025, down from NOK 80.4 million in Q2 2024, with net operating revenues at NOK 67.8 million compared to NOK 72.2 million year-over-year [1] - EBITDA for Q2 2025 was negative NOK 5.4 million, worsening from negative NOK 2.0 million in Q2 2024, while the first six months showed a loss of NOK 25.3 million compared to NOK 18.2 million in the same period last year [2] - Operational EBITDA for Q2 2025 was positive NOK 1.3 million, an improvement from negative NOK 2.5 million in the same quarter last year, while the first six months recorded an Operational EBITDA of negative NOK 7.0 million [2] Liquidity Position - Cash and cash equivalents decreased by NOK 3.9 million during Q2 2025, totaling NOK 68.0 million at the end of the quarter, which is an increase from NOK 25.3 million a year earlier [3] - Total liquidity, including available credit lines, reached NOK 76.5 million as of June 30, 2025 [3] Product and Market Developments - Human Nutrition B2B Sales surged 180% year-over-year to NOK 9.3 million, driven by strong demand in Europe, China, and Southeast Asia [8] - OmeGo® and ProGo® led product launches, supported by scientific validation, with ProGo® winning the "Panpan Cup" Food Maker Award in China [8] - Brilliant Salmon Oil is now available in over 25 countries, with new listings in Italy, Ireland, Taiwan, UAE, and Ecuador, and further distribution agreements in Japan, Czech Republic, and Ukraine are in progress [8] Scientific and Research Advancements - HBC emphasizes scientific evidence, leading to academic partnerships and unique health benefits, including improved iron metabolism and immune health benefits from ProGo® and OmeGo® [7] - CalGo® has shown benefits for bone and joint health, supporting healthy aging and active lifestyles, with ongoing studies and publications planned for ProGo® cognitive health in Alzheimer's [8]

Group 1: ProGo® Product Overview - ProGo® is distinguished by its unique ability to activate GLP-1 and GIP receptors, supported by clinical studies demonstrating weight loss benefits [1] - ProGo® Bioactive Peptides optimize glucose and fat metabolism, enhancing energy levels and promoting a longer active lifestyle [2] Group 2: Company Background - Hofseth BioCare ASA is a Norwegian company focused on sustainability and optimal utilization of natural resources, upcycling byproducts from the salmon industry into health-improving ingredients [3] - The company offers products such as ProGo®, OmeGo® (whole salmon oil), and CalGo® / NT-II™ (salmon bone powder) aimed at improving human and pet health [3] Group 3: Scientific Evidence and Partnerships - Hofseth BioCare emphasizes scientific evidence, leading to academic partnerships and the identification of unique health benefits, including improved iron metabolism and fat reduction in overweight adults with ProGo® [4] - OmeGo® has demonstrated immune health benefits, while CalGo® supports bone and joint health, contributing to healthy aging [4] Group 4: Biotech Ventures - Hofseth BioCare has established a biotech-focused spin-off, HBC Immunology, which has raised external finance and is developing therapeutics for prostate and ovarian cancer, as well as an oral therapy for asthma [4]

Group 1: ProGo® Product Overview - ProGo® is distinguished by its unique ability to activate GLP-1 and GIP receptors, supported by clinical studies demonstrating weight loss [1] - ProGo® Bioactive Peptides optimize glucose and fat metabolism, enhancing energy levels and promoting a longer active lifestyle [2] Group 2: Company Background - Hofseth BioCare ASA is a Norwegian company focused on sustainability and optimal utilization of natural resources, upcycling byproducts from the salmon industry into health-improving ingredients [3] - The company offers products such as ProGo®, OmeGo® (whole salmon oil), and CalGo® / NT-II(TM) (salmon bone powder) aimed at improving human and pet health [3] Group 3: Scientific Evidence and Partnerships - Hofseth BioCare emphasizes scientific evidence, leading to academic partnerships and the identification of unique health benefits, including improved iron metabolism and fat reduction in overweight adults with ProGo® [4] - OmeGo® has demonstrated immune health benefits, while CalGo® supports bone and joint health, contributing to healthy aging [4] Group 4: Biotech Ventures - Hofseth BioCare has established a biotech-focused spin-off, HBC Immunology, which has raised external finance and is developing therapeutics for prostate and ovarian cancer, as well as a therapy for asthma [4]

Company Overview - Hofseth BioCare ASA (HBC) is a Norwegian consumer and pet health company focused on sustainability and optimal utilization of natural resources [1][4] - The company upcycles by converting side streams of the salmon industry into health-improving ingredients for humans and pets [1] Product Offerings - HBC's key products include ProGo®, a mix of bioactive peptides and collagen, OmeGo®, a whole salmon oil, and CalGo® / NT-II®, a salmon bone powder for bone and joint health [2] - ProGo® enhances iron metabolism, leading to increased energy and vitality [3] - OmeGo® provides immune health benefits, aiding recovery from viral infections and improving respiratory health [3] - CalGo® supports bone and joint health, promoting healthy aging and active lifestyles [3] Scientific and Academic Partnerships - HBC emphasizes scientific evidence, resulting in academic partnerships and the identification of unique health benefits [3] - The company has secured patents for its discoveries and has spun out a biotech-focused company, HBC Immunology (HBCI), which is developing therapeutics for prostate and ovarian cancer, as well as an oral therapy for asthma [3] Corporate Structure and Location - HBC is headquartered in Ålesund, Norway, with branches in Oslo, London, Zürich, and Palo Alto [4] - The company is listed on the Oslo Stock Exchange under the ticker "HBC" [4]

Core Insights - HBC reported total operating revenues of NOK 60.9 million in Q1 2025, a 15% increase from NOK 52.4 million in Q1 2024, driven by growth in higher-margin human and pet health segments despite production constraints and commodity oil market pressures [1][6] - The company experienced a significant increase in B2B sales in the human segment, with a 66% year-over-year growth, particularly for products like OmeGo® and ProGo® [6] - HBC launched an unsecured bond that closed after the quarter with subscriptions of approximately CHF 3.5 million, indicating strong investor interest [6] Financial Performance - Cost of goods sold (CoGS) rose to NOK 37.5 million from NOK 27.3 million in Q1 2024, while operating expenses slightly decreased to NOK 23.1 million from NOK 23.9 million [2] - EBITDA for the quarter was negative NOK 19.9 million, compared to NOK -16.2 million in Q1 2024, with operational EBITDA at NOK -8.3 million [3] - The first quarter included NOK 3.0 million in one-time restructuring costs aimed at improving long-term operational efficiency [2][3] Product and Market Developments - HBC's product offerings include ProGo®, OmeGo®, and CalGo® / NT-II®, which are designed to enhance human and pet health [5] - The company achieved a record production period at its Midsund facility, operating 15-20% above its rated capacity while maintaining quality [6] - Clinical studies have shown that OmeGo® significantly reduces coughing and improves sleep in individuals exposed to pollution, while NT-II™ demonstrated improvements in joint pain and stiffness [6][7] Strategic Initiatives - HBC is expanding its production capacity at Berkåk to triple output, reflecting confidence in future demand [6] - The company has made significant advances in pharmaceutical research, including programs targeting prostate cancer and asthma, and has established a biotech-focused spin-off, HBC Immunology [7] - HBC participated in major industry events, reinforcing its leadership in marine-based nutrition and expanding its market presence [6]

Core Insights - Garden of Life, owned by Nestlé, has launched OmeGo® Full Spectrum Omegas, marketed as "Norwegian Salmon Oil," on Amazon in the US, offering a softgel format that retains the nutritional profile of fresh Atlantic salmon [1] - The product is derived from sashimi-grade salmon and provides a full spectrum of omega fatty acids, differentiating itself from competitors that focus primarily on EPA and DHA [2] - Hofseth BioCare ASA (HBC) has published scientific findings highlighting the anti-inflammatory benefits of OmeGo® for immune health, allergies, and sleep quality, following successful clinical studies [3] Product Details - OmeGo® offers a comprehensive range of omega fatty acids, including 3, 5, 6, 7, 9, and 11, along with other health-promoting mediators, emphasizing sustainability from "fjord to shore" [2] - HBC utilizes side streams from the salmon industry to create health-improving ingredients, including ProGo® and CalGo® / NT-II™, which target various health aspects such as bone and joint health [3] Scientific Evidence and Partnerships - HBC prioritizes scientific evidence, leading to academic partnerships and the identification of unique health benefits, such as improved iron metabolism and activation of the GLP-1 receptor for fat reduction [4] - The company has also discovered immune health benefits of OmeGo®, including recovery from viral infections and improved respiratory health, and has secured patents for these findings [4] - HBC has established a biotech-focused spin-off, HBC Immunology, which is pursuing therapeutics for prostate and ovarian cancer, as well as a steroid-sparing therapy for asthma [4]

Group 1: Bond Issuance - The company has successfully placed CHF-denominated unsecured bonds totaling approximately CHF 3.5 million, subscribed by investors in Switzerland and Liechtenstein [2] - The settlement of the bond issue is expected to occur on 5 May 2025, and the bonds will not be listed on any stock exchange or trading venue [2] - The bonds have a term of three years, maturing on 30 April 2028, with an interest rate of 10% per annum and quarterly interest payments starting on 30 September 2025 [3] Group 2: Corporate Purpose and Financial Details - The net proceeds from the bond issuance will be used for general corporate purposes [2] - The bonds are callable at par value at quarterly intervals, with the first call option available on 30 June 2026 [3] Group 3: Company Overview - Hofseth BioCare ASA is a Norwegian consumer and pet health company focused on sustainability and optimal utilization of natural resources [3] - The company upcycles side streams of the salmon industry into health-improving ingredients such as ProGo®, OmeGo®, and CalGo® / NT-II((TM)) [3][4] - Hofseth BioCare emphasizes scientific evidence and has established academic partnerships to identify unique health benefits, including improved iron metabolism and immune health [4] Group 4: Research and Development - The company has received patents for its discoveries and has spun out a biotech-focused company, HBC Immunology, which is developing therapeutics for prostate and ovarian cancer, as well as a therapy for asthma [4]

Company Overview - Hofseth BioCare ASA is a Norwegian consumer and pet health company focused on sustainability and optimal utilization of natural resources [1] - The company upcycles side streams of the salmon industry, converting waste into health-improving ingredients such as ProGo®, OmeGo®, and CalGo® / NT-II(TM) [1] Product Benefits - ProGo® enhances iron metabolism, increasing energy and vitality [2] - OmeGo® provides immune health benefits, aiding recovery from viral infections and improving respiratory health [2] - CalGo® supports bone and joint health, promoting healthy aging and active lifestyles [2] Scientific and Business Developments - Hofseth BioCare has established academic partnerships and secured several patents for its health-related discoveries [2] - The company has spun out HBC Immunology (HBCI), focusing on potential therapeutics, including programs for prostate and ovarian cancer, as well as an oral therapy for asthma [2]